Role of lncRNAs in colorectal cancer

Abstract

Abstract:

Long non-coding RNAs (lncRNAs) are important regulative RNAs whose length are more than 200 nucleotides and cannot be translated into protein. Recent studies have shown that lncRNAs play important roles in the tumor development, invasion and metastasis, early diagnosis, prognosis, chemo-resistance and radio-resistance of colorectal cancer (CRC). CRC is a common gastrointestinal cancer with high morbidity and mortality. Currently, there are some relevant studies on the role of lncRNAs in the development, chemor-esistance and radio-resistance of CRC. Yet this paper reviews the latest international researches in this regard.

Key words: colorectal cancer, lncRNA, tumor

CLC Number:

R968
R735

SUN Yuesheng, QU Qiang, PAN Jianghua, TONG Xiaochun, CHEN Ende, QU Jian. Role of lncRNAs in colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 222-227.

References

［1］Consortium EP. An integrated encyclopedia of DNA elements in the human genome［J］. Nature, 2012, 489(7414): 57-74.
［2］Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world［J］. Genes Dev, 2009, 23(13): 1494-1504.
［3］Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition［J］. Nature, 2014, 505(7483): 344-352.
［4］Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors［J］. Clin Colon Rectal Surg, 2009, 22(4): 191-197.
［5］Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition［J］. Nat Rev Mol Cell Biol, 2014, 15(3): 178-196.
［6］Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers［J］. Cancer Res, 2011, 71(20): 6320-6326.
［7］Dou J, Ni Y, He X, et al. Decreasing lncRNA HOTAIR expression inhibits human colorectal cancer stem cells［J］. Am J Transl Res, 2016, 8(1): 98-108.
［8］Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients［J］. Carcinogenesis, 2014, 35(7): 1510-1515.
［9］Wu ZH, Wang XL, Tang HM, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer［J］. Oncol Rep, 2014, 32(1): 395-402.
［10］Yang XD, Xu HT, Xu XH, et al. Knockdown of long non-coding RNA HOTAIR inhibits proliferation and invasiveness and improves radiosensitivity in colorectal cancer［J］. Oncol Rep, 2016, 35(1): 479-487.
［11］Zhao W, Song M, Zhang J, et al. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma［J］. Int J Clin Exp Pathol, 2015, 8(11): 14131-14140.
［12］Mccleland ML, Mesh K, Lorenzana E, et al. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer［J］. J Clin Invest, 2016, 126(2): 639-652.
［13］Zhai H, Fesler A, Schee K, et al. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer［J］. Clin Colorectal Cancer, 2013, 12(4): 261-266.
［14］Wang J, Lei ZJ, Guo Y, et al. miRNA-regulated delivery of lincRNA-p21 suppresses beta-catenin signaling and tumorigenicity of colorectal cancer stem cells［J］. Oncotarget, 2015, 6(35): 37852-37870.
［15］Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway［J］. Oncol Rep, 2014, 31(4): 1839-1845.
［16］Guo Q, Zhao Y, Chen J, et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition［J］. Oncol Lett, 2014, 8(2): 869-875.
［17］Iguchi T, Uchi R, Nambara S, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer［J］. Anticancer Res, 2015, 35(3): 1385-1388.
［18］Yue B, Qiu S, Zhao S, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis［J］. J Gastroenterol Hepatol, 2016, 31(3): 595-603.
［19］Shen F, Cai WS, Feng Z, et al. Long non-coding RNA SPRY4-IT1 pormotes colorectal cancer metastasis by regulate epithelial-mesenchymal transition［J］. Oncotarget, 2016,［Epub ahead of print］.
［20］Cao D, Ding Q, Yu W, et al. Long noncoding RNA SPRY4-IT1 promotes malignant development of colorectal cancer by targeting epithelial-mesenchymal transition［J］. Onco Targets Ther, 2016, 9: 5417-5425.
［21］Wang L, Zhao Z, Feng W, et al. Long non-coding RNA TUG1 promotes colorectal cancer metastasis via EMT pathway［J］. Oncotarget, 2016,［Epub ahead of print］.
［22］Sun J, Ding C, Yang Z, et al. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition［J］. J Transl Med, 2016, 14: 42.
［23］Han X, Wang L, Ning Y, et al. Long non-coding RNA AFAP1-AS1 facilitates tumor growth and promotes metastasis in colorectal cancer［J］. Biol Res, 2016, 49(1): 36.
［24］Li Q, Dai Y, Wang F, et al. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer［J］. Neoplasma, 2016, 63(6): 977-983.
［25］Yin D, He X, Zhang E, et al. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer［J］. Med Oncol, 2014, 31(11): 253.
［26］Kong H, Wu Y, Zhu M, et al. Long non-coding RNAs: novel prognostic biomarkers for liver metastases in patients with early stage colorectal cancer［J］. Oncotarget, 2016, ［Epub ahead of print］.
［27］Krell J, Frampton AE, Mirnezami R, et al. Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer［J］. PLoS One, 2014, 9(6): e98561.
［28］Naemura M, Tsunoda T, Inoue Y, et al. ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture［J］. Mol Cell Biochem, 2016, 412(1/2): 141-146.
［29］Sun Y, Zheng ZP, Li H, et al. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro［J］. Mol Med Rep, 2016, 14(2): 1714-1720.
［30］Ren YK, Xiao Y, Wan XB, et al. Association of long non-coding RNA HOTTIP with progression and prognosis in colorectal cancer［J］. Int J Clin Exp Pathol, 2015, 8(9): 11458-11463.
［31］Lian Y, Ding J, Zhang Z, et al. The long noncoding RNA HOXA transcript at the distal tip promotes colorectal cancer growth partially via silencing of p21 expression［J］. Tumor Biol, 2016, 37(6): 7431-7440.
［32］Han D, Gao X, Wang M, et al. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3［J］. Oncotarget, 2016, 7(16): 22159-22173.
［33］Thorenoor N, Faltejskova-Vychytilova P, Hombach S, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer［J］. Oncotarget, 2016, 7(1): 622-637.
［34］Hu ZY, Wang XY, Guo WB, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells［J］. Oncotarget, 2016, 7(10): 11733-11743.
［35］Yang MH, Hu ZY, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9［J］. Biochim Biophys Acta, 2015, 1852(1): 166-174.
［36］Kan JY, Wu DC, Yu FJ, et al. Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1［J］. J Cell Physiol, 2015, 230(8): 1883-1894.
［37］Xu C, Yang M, Tian J, et al. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis［J］. Int J Oncol, 2011, 39(1): 169-175.
［38］Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer［J］. Int J Clin Exp Pathol, 2014, 7(6): 3174-3181.
［39］Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer［J］. Oncotarget, 2015, 6(26): 22513-22525.
［40］Tsang WP, Ng EK, Ng SS, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer［J］. Carcinogenesis, 2010, 31(3): 350-358.
［41］Ling H, Spizzo R, Atlasi Y, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer［J］. Genome Res, 2013, 23(9): 1446-1461.
［42］Han Y, Yang YN, Yuan HH, et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution［J］. Pathology, 2014, 46(5): 396-401.
［43］Ni B, Yu X, Guo X, et al. Increased urothelial cancer associated 1 is associated with tumor proliferation and metastasis and predicts poor prognosis in colorectal cancer［J］. Int J Oncol, 2015, 47(4): 1329-1338.
［44］Bian Z, Jin L, Zhang J, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p［J］. Sci Rep, 2016, 6: 23892.
［45］Li Y, Li Y, Chen W, et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer［J］. Oncotarget, 2015, 6(29): 27641-27650.
［46］Wu Y, Yang L, Zhao J, et al. Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer［J］. Mol Cancer, 2015, 14: 191.
［47］Yin DD, Liu ZJ, Zhang E, et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer［J］. Tumor Biol, 2015, 36(6): 4851-4859.
［48］Cao X, Zhuang S, Hu Y, et al. Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese［J］. Oncotarget, 2016, 7(14): 19054-19059.
［49］Lee H, Kim C, Ku JL, et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells［J］. Mol Cells, 2014, 37(7): 540-546.
［50］Liu X, Jiao T, Wang Y, et al. Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer［J］. Minerva Med, 2016,［Epub ahead of print］.
［51］Yue B, Cai D, Liu C, et al. Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer［J］. Mol Ther, 2016,［Epub ahead of print］.
［52］Ma Y, Yang Y, Wang F, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signalling pathway via suppression of activator protein 2alpha［J］. Gut, 2016, 65(9): 1494-1504.

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[3]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[4]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[5]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[6]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[7]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[8]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[9]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[10]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[11]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[12]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[13]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[14]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[15]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.